Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 12/20 | 0.42 |
| ▸ | LTA4H | P09960 | 3/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 2/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5108309 | 0.90 | ESR1 (0.49) | ESR1ESR2LTA4HAURKBGRIN2B | |
| SCHEMBL5108800 | 0.90 | GRIN1 (0.41) | ESR1ESR2LTA4HGRIN2BNPY1R | |
| SCHEMBL5104687 | 0.89 | ESR1 (0.46) | ESR1ESR2LTA4HGRIN2BNPY1R | |
| SCHEMBL5101675 | 0.86 | ESR1 (0.60) | ESR1ESR2LTA4HGRIN2BNPY1R | |
| SCHEMBL5105378 | 0.85 | ESR1 (0.41) | ESR1ESR2LTA4HGRIN2B | |
| SCHEMBL5115012 | 0.85 | ESR1 (0.46) | ESR1ESR2GRIN2BNPY1RMLNR | |
| SCHEMBL5104973 | 0.85 | ESR1 (0.48) | ESR1ESR2GRIN2B | |
| SCHEMBL5105667 | 0.85 | ESR1 (0.48) | ESR1ESR2LTA4HGRIN2B | |
| SCHEMBL14032394 | 0.84 | ESR1 (0.55) | ESR1ESR2NPY1RMLNRNR1I2 | |
| SCHEMBL5115570 | 0.83 | KDM4E (0.48) | ESR1ESR2GRIN2BDRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435729-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6686351-B2 | PARTIALLY HYDROGENATED FUSED INDENE, NAPHTHALENE, ISOINDOLE, ISOQUINOLINE, BENZOAZEPINE AND BENZOCYCLOHEPTENE DERIVATIVES SUBSTITUTED BY A HYDROXY GROUP OR DERIVATIVE AND AN ARYL OR N-HETEROARYL GROUP | SIGNAL PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6593322-B1 | Methods are disclosed for modulating ER- beta in cell and/or tissues expressing the same, including cells and/ or tissue that preferentially ER- beta . Methods for treating estrogen-related conditions are also disclosed, including | SIGNAL PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| EP-1322617-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-07-02 | — | — | EP | disclosed |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6436923-B1 | ESTROGEN ANTAGONISTS AND/OR AGONISTS FOR TREATING ESTROGEN-RELATED CONDITIONS | SIGNAL PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
| WO-2002024653-A1 | COMPOUNDS AND METHODS FOR MODULATION OF ESTROGEN RECEPTORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | ESR1 5/4885ESR2 3/4885LTA4H 3967/4885 |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | ESR1 6/4885ESR2 3/4885LTA4H 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.